Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

MSN
2025.11.29 18:23
portai
I'm PortAI, I can summarize articles.

Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG, citing positive findings from CRISPR's presentation on CTX310 at the American Heart Association, despite a slowdown in Casgevy.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer